시장보고서
상품코드
1500098

세계의 호흡기 진단 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 검사 유형별, 질환 적응증별, 최종 용도별, 지역별, 경쟁(2019-2029년)

Respiratory Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Test Type, By Disease Indication, By End-Use, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

호흡기 진단 시장 규모는 2023년에 57억 1,000만 달러로 평가되었고, 2029년까지 복합 연간 성장률(CAGR) 6.73%로 꾸준한 성장이 예측되고 있습니다.

세계 호흡기 진단 시장은 호흡기 질환의 유병률 증가와 조기 및 정확한 진단 솔루션의 중시 증가로 보다 광범위한 건강 관리 산업에서 역동적이고 중요한 분야로 부상하고 있습니다. 이 시장에는 만성 폐색성 폐질환(COPD), 천식, 호흡기 감염과 같은 호흡기 질환을 평가하고 모니터링하도록 설계된 다양한 진단 도구 및 장비가 포함됩니다. 시장을 촉진하는 주요 요인은 대기 오염, 담배 사용, 노화 등의 요인으로 인해 호흡기 질환의 세계 부담이 증가하고 있다는 것입니다. 기술의 진보는 정교한 이미징 기술에서 분자진단 및 신속한 요점 검사에 이르기까지 상황을 형성하는 데 매우 중요한 역할을합니다. 이러한 기술을 통해 건강 관리 전문가는 호흡기 질환을 보다 효율적으로 진단할 수 있어 시기 적절한 개입과 맞춤 치료 계획을 용이하게 합니다.

시장 개요
예측 기간 2025-2029
시장 규모 : 2023년 57억 1,000만 달러
시장 규모 : 2029년 83억 6,000만 달러
복합 연간 성장률(CAGR): 2024년-2029년 6.73%
급성장 부문 분석 및 시약
최대 시장 북미

조기 진단과 질병 관리의 중요성에 대한 인식이 높아지고 호흡기 진단에 대한 수요가 급증하고 있습니다. 환자와 건강 관리 제공업체 모두 호흡기 질환을 발병시 확인하는 것이 중요하다는 것을 알고 있으며, 이는 질병 진행을 완화하고 환자의 예후를 개선하기 위한 예방적 조치를 가능하게 합니다. COVID-19의 세계적인 유행은 검사 기법과 인프라의 급속한 발전을 촉진하고 호흡기 진단의 중요한 역할을 더욱 강조합니다. 분자 분석 및 혈청학적 검사를 포함한 진단 검사는 COVID-19의 원인인 SARS-CoV-2 바이러스에 초점을 맞춘 호흡기 감염의 확인 및 모니터링에 매우 중요합니다. 시장 개척 기업은 또한 휴대용 비침습 장치를 포함한 새로운 진단 솔루션을 도입하기 위한 R&D에 투자하고 있으며 호흡기 검사의 분산화를 촉진하고 환자의 접근성을 높이고 있습니다. 또한 진단기업과 의료기관의 협업은 혁신적인 기술과 솔루션을 제공하여 호흡기 진단의 지속적인 진화에 기여하고 있습니다.

시장 성장 촉진요인

호흡기 질환의 유행

세계 고령화

주요 시장 과제

진단의 복잡성

숙련된 인재 확보

주요 시장 동향

조기 및 정확한 진단의 중요성 증가

원격 의료 및 원격 모니터링

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계 호흡기 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율,예측
    • 유형별(기기 및 장치, 분석 및 시약, 서비스 및 소프트웨어)
    • 검사유형별(기계적 검사, OSA 진단 검사, 화상 검사, 종래의 진단 검사, 분자진단 검사)
    • 질환별(결핵, 천식, 폐암, 만성 폐색성 폐 질환, 기타)
    • 용도별(병원 및 진료소, 진단 실험실, 기타)
    • 지역별
    • 기업별(2023)
  • 시장 맵
    • 유형별
    • 검사 유형별
    • 질환 적응증별
    • 최종 용도별
    • 지역별

제6장 아시아태평양의 호흡기 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율,예측
    • 유형별
    • 검사 유형별
    • 질환 적응증별
    • 최종 용도별
    • 국가별
  • 아시아태평양: 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제7장 유럽의 호흡기 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율,예측
    • 유형별
    • 검사 유형별
    • 질환 적응증별
    • 최종 용도별
    • 국가별
  • 유럽: 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제8장 북미의 호흡기 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율,예측
    • 유형별
    • 검사 유형별
    • 질환 적응증별
    • 최종 용도별
    • 국가별
  • 북미: 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제9장 남미의 호흡기 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율,예측
    • 유형별
    • 검사 유형별
    • 질환 적응증별
    • 최종 용도별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 호흡기 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율,예측
    • 유형별
    • 검사 유형별
    • 질환 적응증별
    • 최종 용도별
    • 국가별
  • 중동 및 아프리카: 국가별 분석
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이집트

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 최근 동향
  • 제품상시
  • 합병과 인수

제13장 세계 호흡기 진단 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

  • 업계 내 경쟁
  • 신규 진입의 가능성
  • 공급자의 힘
  • 고객의 힘
  • 대체품의 위협

제15장 경쟁 구도

  • Koninklijke Philips NV
  • Beckton, Dickson and Company
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories Inc.
  • Dragerwerk AG & Co. KGaA
  • Siemens Healthineers AG
  • PerkinElmer Inc.
  • India Medtronic Private Limited
  • Bio-Rad Laboratories, Inc.
  • GE HealthCare Technologies Inc.

제16장 전략적 제안

제17장 기업 소개와 면책사항

BJH 24.07.04

Global Respiratory Diagnostics Market was valued at USD 5.71 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.73% through 2029. The Global Respiratory Diagnostics Market has emerged as a dynamic and crucial sector within the broader healthcare industry, driven by the increasing prevalence of respiratory diseases and a growing emphasis on early and accurate diagnostic solutions. This market encompasses a diverse range of diagnostic tools and devices designed to evaluate and monitor respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and respiratory infections. Key drivers propelling the market include the rising global burden of respiratory illnesses, spurred by factors such as air pollution, tobacco use, and an aging population. Technological advancements play a pivotal role in shaping the landscape of respiratory diagnostics, with innovations ranging from advanced imaging techniques to molecular diagnostics and rapid point-of-care testing. These technologies enable healthcare professionals to diagnose respiratory conditions more efficiently, facilitating timely interventions and personalized treatment plans.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 5.71 Billion
Market Size 2029USD 8.36 Billion
CAGR 2024-20296.73%
Fastest Growing SegmentAssays & Reagents
Largest MarketNorth America

The increased awareness of the importance of early diagnosis and disease management has prompted a surge in demand for respiratory diagnostics. Patients and healthcare providers alike recognize the significance of identifying respiratory conditions at their onset, allowing for proactive measures to mitigate the progression of diseases and improve patient outcomes. The global COVID-19 pandemic has further underscored the critical role of respiratory diagnostics, driving rapid developments in testing methodologies and infrastructure. Diagnostic tests, including molecular assays and serological tests, have been pivotal in identifying and monitoring respiratory infections, with a focus on the SARS-CoV-2 virus responsible for COVID-19. Market players are also investing in research and development to introduce novel diagnostic solutions, including portable and non-invasive devices, fostering the decentralization of respiratory testing and enhancing accessibility for patients. Additionally, collaborations between diagnostic companies and healthcare institutions contribute to the continuous evolution of respiratory diagnostics, bringing forth innovative technologies and solutions.

Key Market Drivers

Prevalence of Respiratory Diseases

The prevalence of respiratory diseases serves as a paramount driver for the Global Respiratory Diagnostics Market, underscoring the critical need for accurate and timely diagnostic solutions. Chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD), asthma, and respiratory infections, have become increasingly prevalent on a global scale. Contributing factors include environmental pollutants, occupational exposures, lifestyle choices, and an aging population. As the incidence of these respiratory ailments continues to rise, the demand for advanced and efficient diagnostic tools becomes imperative for effective disease management. The aging population is particularly susceptible to respiratory issues, and as the demographic landscape shifts towards an older age structure globally, the burden of respiratory diseases intensifies.

Older individuals often experience age-related respiratory conditions, making early detection and diagnosis crucial for implementing timely interventions. Moreover, the growing awareness among individuals regarding the impact of environmental factors on respiratory health drives a proactive approach to seek respiratory diagnostics for preventive healthcare measures. The COVID-19 pandemic has further accentuated the significance of respiratory diagnostics in the context of global respiratory infections. The heightened focus on testing and monitoring respiratory infections has accelerated advancements in diagnostic technologies. Collectively, the prevalence of respiratory diseases acts as a catalyst, propelling the continuous evolution and expansion of the respiratory diagnostics market to meet the increasing demand for precise and efficient diagnostic solutions in the face of the growing respiratory health challenges worldwide.

Global Aging Population

The Global Respiratory Diagnostics Market is significantly influenced by the aging population worldwide. As demographic patterns shift towards an increasingly older populace, the prevalence of respiratory conditions tends to rise, necessitating a heightened focus on respiratory diagnostics. Aging is associated with a higher susceptibility to respiratory ailments, including chronic obstructive pulmonary disease (COPD), pneumonia, and other age-related respiratory issues. The anatomical and physiological changes that accompany aging, such as reduced lung elasticity and weakened respiratory muscles, contribute to an elevated risk of respiratory disorders.

The demand for advanced diagnostic tools becomes more pronounced to facilitate early detection and proactive management of respiratory diseases in the elderly. The aging population's greater vulnerability to respiratory infections, coupled with a potential decline in immune function, underscores the importance of respiratory diagnostics in this demographic. Timely and accurate diagnostic solutions are essential for tailoring effective interventions and optimizing treatment outcomes for elderly individuals with respiratory conditions. The Global Respiratory Diagnostics Market responds to this demographic imperative by continually innovating diagnostic technologies, embracing portability and non-invasiveness, and enhancing accessibility to diagnostic services. As the aging population continues to expand, the market for respiratory diagnostics is poised to play a pivotal role in addressing the unique healthcare challenges associated with respiratory health in older individuals, contributing to improved quality of life and enhanced healthcare outcomes for this demographic segment.

Key Market Challenges

Complexity in Diagnosis

The Global Respiratory Diagnostics Market grapples with the inherent complexity in diagnosing respiratory conditions, presenting a significant challenge to accurate and timely disease identification. Respiratory diseases often exhibit a spectrum of symptoms that can overlap, making it intricate to differentiate between conditions such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections solely based on clinical presentation. This complexity necessitates sophisticated and multi-faceted diagnostic approaches, including advanced imaging techniques, molecular diagnostics, and pulmonary function tests. Moreover, the challenge of diagnosing respiratory diseases is compounded by the diversity of potential causes, ranging from environmental factors and occupational exposures to genetic predispositions. The intricate interplay of these variables requires comprehensive diagnostic tools that can discern subtle nuances in disease presentation and etiology.

In addition, the need for differential diagnosis is amplified by the existence of comorbidities, where individuals may concurrently experience multiple respiratory conditions. Unraveling this diagnostic complexity is crucial for tailoring appropriate treatment strategies and interventions. Advanced technologies, such as precision medicine and personalized diagnostics, are increasingly being explored to address the intricate nature of respiratory disease diagnosis by considering individual patient characteristics and genetic factors. As the Global Respiratory Diagnostics Market continues to evolve, the industry faces the ongoing challenge of developing and refining diagnostic tools that can navigate the intricate landscape of respiratory diseases. Overcoming the complexity in diagnosis requires ongoing research, technological innovation, and collaborative efforts to enhance the specificity and sensitivity of diagnostic methods, ultimately improving patient outcomes and optimizing respiratory healthcare delivery.

Availability of Skilled Personnel

The availability of skilled personnel poses a significant challenge to the Global Respiratory Diagnostics Market, impacting the effective implementation and utilization of advanced diagnostic technologies. Operating and interpreting results from sophisticated respiratory diagnostic tools, such as molecular assays, imaging techniques, and pulmonary function tests, often requires specialized training and expertise. However, there is a shortage of healthcare professionals with the necessary skills and proficiency in utilizing these technologies, particularly in resource-limited settings and underserved regions. The complexity of respiratory diseases and the diverse range of diagnostic modalities available further exacerbate the challenge of skilled personnel availability. Healthcare professionals need to possess a comprehensive understanding of respiratory anatomy and physiology, as well as proficiency in interpreting diagnostic results accurately to facilitate timely diagnosis and appropriate treatment decisions.

Staying abreast of advancements in respiratory diagnostics requires continuous education and training, which may not always be readily accessible to healthcare professionals in all regions. Addressing the shortage of skilled personnel in respiratory diagnostics requires concerted efforts from various stakeholders. This includes investing in specialized training programs and continuing education opportunities for healthcare professionals to enhance their diagnostic skills. Collaboration between academic institutions, healthcare organizations, and industry partners can facilitate the development of tailored training programs that address the specific needs of respiratory diagnostics. Also, leveraging telemedicine and digital health platforms can extend the reach of skilled personnel to remote or underserved areas, ensuring broader access to respiratory diagnostic expertise and improving healthcare outcomes for patients worldwide.

Key Market Trends

Increased Emphasis on Early and Accurate Diagnosis

The Global Respiratory Diagnostics Market is witnessing a pronounced trend marked by an increased emphasis on early and accurate diagnosis of respiratory conditions. This shift is driven by a recognition of the substantial benefits associated with timely disease identification, leading to improved patient outcomes and more effective management of respiratory disorders. Advances in diagnostic technologies, including molecular testing, advanced imaging modalities, and novel biomarkers, have facilitated a more precise and rapid diagnosis of respiratory diseases. Early diagnosis is particularly crucial in respiratory health, as it enables healthcare professionals to initiate timely interventions, tailor treatment plans, and prevent the progression of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. The integration of point-of-care testing, offering quick and convenient diagnostic results, further supports this trend, especially in settings where immediate decision-making is imperative.

The growing understanding of the impact of respiratory diseases on public health has heightened the importance of proactive healthcare measures. Screening programs and routine respiratory diagnostics have become integral components of preventive healthcare strategies. Patients and healthcare providers alike recognize that early detection not only enhances treatment efficacy but also reduces the economic burden associated with advanced-stage respiratory diseases. As the Global Respiratory Diagnostics Market continues to evolve, the increased emphasis on early and accurate diagnosis is expected to drive innovation, encourage research and development, and ultimately contribute to a paradigm shift in respiratory healthcare, fostering a future where proactive diagnostics play a central role in preserving respiratory health worldwide.

Telehealth and Remote Monitoring

Telehealth and remote monitoring have emerged as transformative trends in the Global Respiratory Diagnostics Market, especially accelerated by the paradigm shift induced by the COVID-19 pandemic. These technologies play a pivotal role in reshaping how respiratory diagnostics are conducted, providing opportunities for remote consultations, continuous patient monitoring, and accessible healthcare delivery. The adoption of telehealth platforms facilitates virtual consultations, enabling individuals to connect with healthcare professionals for respiratory assessments without the need for physical visits to medical facilities. This has proven particularly valuable in ensuring continued respiratory care during times of social distancing and lockdowns. Remote monitoring technologies offer a real-time and continuous assessment of respiratory parameters, providing crucial data for the early detection and management of respiratory conditions.

Wearable devices, smart inhalers, and other connected technologies enable healthcare providers to remotely track patients' respiratory health, optimizing personalized treatment plans and improving overall disease management. These innovations not only enhance patient convenience but also contribute to better adherence to treatment regimens and timely interventions. The integration of telehealth and remote monitoring in the respiratory diagnostics landscape not only addresses the challenges posed by geographical barriers but also supports proactive healthcare measures. Patients with chronic respiratory conditions can benefit from regular monitoring and timely adjustments to their treatment plans, reducing the risk of exacerbations and hospitalizations. As the Global Respiratory Diagnostics Market continues to evolve, the synergy between telehealth, remote monitoring, and respiratory diagnostics is poised to redefine patient care, fostering a future where healthcare is increasingly accessible, personalized, and proactive.

Segmental Insights

Type Insights

Based on Type, Assays & Reagents have emerged as fastest growing segment in the Global Respiratory Diagnostics Market in 2023. This is ascribed due to its fundamental role in detecting and analyzing respiratory infections. Assays and reagents form the core components of diagnostic tests, enabling the identification of respiratory pathogens, biomarkers, and specific antibodies. The growing prevalence of respiratory diseases and infections fuels the demand for accurate and efficient diagnostic tools. Ongoing advancements in assay technologies contribute to the segment's dominance, facilitating rapid and precise respiratory diagnostics. The Assays & Reagents segment's central role in enhancing diagnostic capabilities positions it as a key driver, influencing the trajectory of the Global Respiratory Diagnostics Market.

End-Use Insights

Based on End-Use, Hospitals and Clinics have emerged as dominating segment in the Global Respiratory Diagnostics Market in 2023. Hospitals and clinics play a pivotal role as primary destinations for individuals seeking respiratory diagnostic services. Patients frequently rely on these healthcare facilities for initial evaluation, diagnosis, and treatment of respiratory conditions, resulting in a significant demand for diagnostic tests. By offering comprehensive healthcare services, including respiratory diagnostics, within a single location, hospitals and clinics promote convenience, encouraging patients to undergo diagnostic procedures and promptly address respiratory ailments. Moreover, hospitals often feature specialized departments and respiratory care units staffed with skilled healthcare professionals, such as pulmonologists and respiratory therapists. These experts possess the knowledge and proficiency to administer and interpret intricate respiratory diagnostic tests, thereby elevating the standard of care provided.

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Respiratory Diagnostics Market in 2023. North America's advanced healthcare infrastructure features cutting-edge diagnostic facilities and state-of-the-art medical technologies, enabling early detection and diagnosis of respiratory conditions, thus propelling market expansion. With a notable prevalence of respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, the region undergoes extensive diagnostic testing, further solidifying its market dominance. Moreover, North America leads the way in developing and adopting innovative respiratory diagnostic technologies, including advanced imaging methods, molecular diagnostics, and point-of-care testing systems, reinforcing its stronghold in the market.

Key Market Players

Koninklijke Philips N.V

Becton, Dickinson and Company

Thermo Fisher Scientific Inc.

Abbott Laboratories Inc.

Dragerwerk AG & Co. KGaA

Siemens Healthineers AG

PerkinElmer Inc.

India Medtronic Private Limited

Bio-Rad Laboratories, Inc.

GE HealthCare Technologies Inc.

Report Scope:

In this report, the Global Respiratory Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Diagnostics Market, By Type:

    Instruments and Devices Assays & Reagents Services & Software

Respiratory Diagnostics Market, By Test Type:

    Mechanical Tests OSA Diagnostic Test Imaging Tests Traditional Diagnostic Test Molecular Diagnostic Test

Respiratory Diagnostics Market, By Disease Indication:

    Tuberculosis Asthma Lung Cancer Chronic Obstructive Pulmonary Disease Others

Respiratory Diagnostics Market, By End-Use:

    Hospitals and Clinics Diagnostics Laboratory Others

Respiratory Diagnostics Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Respiratory Diagnostics Market.

Available Customizations:

Global Respiratory Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Instruments and Devices, Assays & Reagents, Services & Software)
    • 5.2.2. By Test Type (Mechanical Tests, OSA Diagnostic Test, Imaging Tests, Traditional Diagnostic Test, Molecular Diagnostic Tests)
    • 5.2.3. By Disease Indication (Tuberculosis, Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease, Others)
    • 5.2.4. By End-Use (Hospitals and Clinics, Diagnostics Laboratory, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Test Type
    • 5.3.3. By Disease Indication
    • 5.3.4. By End-Use
    • 5.3.5. By Region

6. Asia Pacific Respiratory Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Test Type
    • 6.2.3. By Disease Indication
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Respiratory Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Disease Indication
        • 6.3.1.2.4. By End-Use
    • 6.3.2. India Respiratory Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Disease Indication
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Australia Respiratory Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Disease Indication
        • 6.3.3.2.4. By End-Use
    • 6.3.4. Japan Respiratory Diagnostics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Test Type
        • 6.3.4.2.3. By Disease Indication
        • 6.3.4.2.4. By End-Use
    • 6.3.5. South Korea Respiratory Diagnostics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Test Type
        • 6.3.5.2.3. By Disease Indication
        • 6.3.5.2.4. By End-Use

7. Europe Respiratory Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Test Type
    • 7.2.3. By Disease Indication
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Respiratory Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Disease Indication
        • 7.3.1.2.4. By End-Use
    • 7.3.2. Germany Respiratory Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Disease Indication
        • 7.3.2.2.4. By End-Use
    • 7.3.3. Spain Respiratory Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Disease Indication
        • 7.3.3.2.4. By End-Use
    • 7.3.4. Italy Respiratory Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Disease Indication
        • 7.3.4.2.4. By End-Use
    • 7.3.5. United Kingdom Respiratory Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Disease Indication
        • 7.3.5.2.4. By End-Use

8. North America Respiratory Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Test Type
    • 8.2.3. By Disease Indication
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Respiratory Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Disease Indication
        • 8.3.1.2.4. By End-Use
    • 8.3.2. Mexico Respiratory Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Disease Indication
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Canada Respiratory Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Disease Indication
        • 8.3.3.2.4. By End-Use

9. South America Respiratory Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Test Type
    • 9.2.3. By Disease Indication
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Respiratory Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Disease Indication
        • 9.3.1.2.4. By End-Use
    • 9.3.2. Argentina Respiratory Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Disease Indication
        • 9.3.2.2.4. By End-Use
    • 9.3.3. Colombia Respiratory Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Disease Indication
        • 9.3.3.2.4. By End-Use

10. Middle East and Africa Respiratory Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Test Type
    • 10.2.3. By Disease Indication
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Respiratory Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Disease Indication
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Saudi Arabia Respiratory Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Disease Indication
        • 10.3.2.2.4. By End-Use
    • 10.3.3. UAE Respiratory Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Disease Indication
        • 10.3.3.2.4. By End-Use
    • 10.3.4. Egypt Respiratory Diagnostics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Test Type
        • 10.3.4.2.3. By Disease Indication
        • 10.3.4.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Respiratory Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Koninklijke Philips N.V
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Beckton, Dickson and Company
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Abbott Laboratories Inc.
  • 15.5. Dragerwerk AG & Co. KGaA
  • 15.6. Siemens Healthineers AG
  • 15.7. PerkinElmer Inc.
  • 15.8. India Medtronic Private Limited
  • 15.9. Bio-Rad Laboratories, Inc.
  • 15.10. GE HealthCare Technologies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제